A flow cytometry-based assay system for the in vitro screening of anti-steatotic compounds. (PubMed, In Vitro Model) - Sep 21, 2026 - "The assay was validated using known anti-steatotic drugs, where Saroglitazar, Pioglitazone, Empagliflozin, and Atorvastatin significantly reduced lipid accumulation in HepG2 cells. The present flow cytometry assay is a human cell-based and animal-free system that offers a sensitive, accurate, and high-throughput platform for evaluating anti-steatotic compounds, with clear advantages over conventional methods for early-stage drug discovery. The online version contains supplementary material available at https://doi.org/10.1007/s44164-026-00110-4."
Journal • Preclinical • Hepatology • Metabolic Dysfunction-Associated Steatotic Liver Disease
|
|
Kajal Deshmukh; Navya Malladi; Sanjay K Banerjee
|